PL3053932T3 - Nowe immunoadhezyny CTLA4-IG - Google Patents

Nowe immunoadhezyny CTLA4-IG

Info

Publication number
PL3053932T3
PL3053932T3 PL15198516T PL15198516T PL3053932T3 PL 3053932 T3 PL3053932 T3 PL 3053932T3 PL 15198516 T PL15198516 T PL 15198516T PL 15198516 T PL15198516 T PL 15198516T PL 3053932 T3 PL3053932 T3 PL 3053932T3
Authority
PL
Poland
Prior art keywords
immunoadhesins
ctla4
new
new ctla4
Prior art date
Application number
PL15198516T
Other languages
English (en)
Inventor
Gregory A. Lazar
Matthew J. Bernett
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of PL3053932T3 publication Critical patent/PL3053932T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
PL15198516T 2010-02-19 2011-02-22 Nowe immunoadhezyny CTLA4-IG PL3053932T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30631110P 2010-02-19 2010-02-19
US33480610P 2010-05-14 2010-05-14
US41230910P 2010-11-10 2010-11-10
EP15198516.5A EP3053932B1 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins
EP11727563.6A EP2536745B1 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins
PCT/US2011/025747 WO2011103584A2 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins

Publications (1)

Publication Number Publication Date
PL3053932T3 true PL3053932T3 (pl) 2021-03-08

Family

ID=44483626

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15198516T PL3053932T3 (pl) 2010-02-19 2011-02-22 Nowe immunoadhezyny CTLA4-IG
PL11727563T PL2536745T3 (pl) 2010-02-19 2011-02-22 Nowe immunoadhezyny CTLA4-IG

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11727563T PL2536745T3 (pl) 2010-02-19 2011-02-22 Nowe immunoadhezyny CTLA4-IG

Country Status (19)

Country Link
US (8) US8329867B2 (pl)
EP (2) EP2536745B1 (pl)
JP (1) JP5705242B2 (pl)
KR (1) KR101926663B1 (pl)
CN (3) CN113372451B (pl)
AU (2) AU2011217770B2 (pl)
CA (1) CA2790487C (pl)
CY (2) CY1118001T1 (pl)
DK (2) DK3053932T3 (pl)
ES (2) ES2826894T3 (pl)
HR (2) HRP20160938T1 (pl)
HU (2) HUE050768T2 (pl)
LT (2) LT2536745T (pl)
PL (2) PL3053932T3 (pl)
PT (1) PT3053932T (pl)
RS (1) RS61136B1 (pl)
SI (2) SI2536745T1 (pl)
SM (2) SMT202000572T1 (pl)
WO (1) WO2011103584A2 (pl)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
EP2545073B1 (en) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
KR101536151B1 (ko) * 2012-01-31 2015-07-14 서울대학교산학협력단 새로운 ＣＴＬＡ-４ＩｇＧ 융합 단백질
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
ES2777778T3 (es) * 2012-05-11 2020-08-06 Medimmune Ltd Variantes de CTLA-4
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
EP2855533A4 (en) * 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US20150004161A1 (en) * 2013-07-01 2015-01-01 University Of Maryland Fc Coupled Compositions and Methods of Their Use
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
MX388181B (es) 2014-07-22 2025-03-19 Cb Therapeutics Inc Anticuerpos anti-pd-1.
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
RS61943B1 (sr) 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
KR20200091499A (ko) 2015-05-06 2020-07-30 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
US10479838B2 (en) 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
UA125433C2 (uk) * 2015-07-23 2022-03-09 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Націлена на іl-23а і фактор активації в-лімфоцитів (baff) сполука та її застосування
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
WO2018089423A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
EP3586136B1 (en) 2017-02-24 2023-11-08 Board Of Regents, The University Of Texas System Assay for detection of early stage pancreatic cancer
WO2018161092A1 (en) 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
EP3596114A2 (en) * 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
AU2018281830B2 (en) 2017-06-09 2023-11-02 Agonox, Inc. Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
PT3587445T (pt) * 2017-08-10 2024-03-14 Grifols Diagnostic Solutions Inc Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
CA3081336A1 (en) 2017-10-12 2019-04-18 Gregory LIZEE T cell receptors for immunotherapy
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
EP3707165A4 (en) 2017-11-07 2021-09-08 The Board of Regents of The University of Texas System LILRB4 TARGETING WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2019118826A1 (en) 2017-12-15 2019-06-20 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019173223A1 (en) * 2018-03-05 2019-09-12 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202009504YA (en) 2018-03-25 2020-10-29 Snipr Biome Aps Treating & preventing microbial infections
CA3094108A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas Systems Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
AU2019274826A1 (en) * 2018-05-25 2021-01-07 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
CA3106384A1 (en) * 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
US12492380B2 (en) 2019-05-09 2025-12-09 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
WO2020236562A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
BR112021026410A2 (pt) 2019-07-01 2022-02-08 Tonix Pharma Ltd Anticorpos anti-cd154 e usos dos mesmos
EP4017529A4 (en) * 2019-08-22 2024-03-13 Cidara Therapeutics, Inc. FIELDS FC VARIANTS AND THEIR USES
US12312414B2 (en) 2019-09-18 2025-05-27 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3161733A1 (en) 2020-01-07 2021-05-15 Everett Stone Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
JP2023510308A (ja) 2020-01-10 2023-03-13 モデルナティエックス インコーポレイテッド 寛容原性樹状細胞を作る方法
WO2021155113A1 (en) 2020-01-29 2021-08-05 Board Of Regents, The University Of Texas System Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
US20230069749A1 (en) 2020-01-29 2023-03-02 Board Of Regents, The University Of Texas System Use of poziotinib for the treatment of cancers with nrg1 fusions
EP4096720A2 (en) 2020-01-30 2022-12-07 ModernaTX, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202208418A (zh) 2020-05-21 2022-03-01 美國德州系統大學評議委員會 具有vgll1特異性之t細胞受體及其用途
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
JP2024503625A (ja) 2021-01-06 2024-01-26 トニックス ファーマ リミテッド 改変された抗ｃｄ１５４抗体により免疫寛容を誘導する方法
CA3205538A1 (en) 2021-01-19 2022-07-28 Han XIAO Bone-specific delivery of polypeptides
WO2022192536A1 (en) * 2021-03-11 2022-09-15 The Methodist Hospital Methods and compositions for treatment of disease
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
MX2024004122A (es) 2021-10-05 2024-05-13 Cytovia Therapeutics Llc Células citolíticas (asesinas) naturales y métodos de uso de las mismas.
PE20242001A1 (es) 2021-10-20 2024-09-27 Takeda Pharmaceuticals Co Composiciones que actuan sobre bcma y metodos de uso de estas
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
AU2022378755A1 (en) * 2021-10-28 2024-06-06 Monash University Variant ctla4 proteins
CA3242953A1 (en) * 2021-12-17 2025-04-29 Kashiv Biosciences, Llc IMPROVED METHOD FOR SEPARATION OF LOW MOLECULAR WEIGHT PROTEINS
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
KR20250113537A (ko) 2022-10-25 2025-07-25 아블렉시스, 엘엘씨 항-cd3 항체
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
EP4688856A1 (en) 2023-04-03 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies
WO2026064599A1 (en) 2024-09-19 2026-03-26 Zenas Biopharma, Inc. Stable formulations for ctla4-ig fusion proteins and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CN1443850A (zh) * 2002-03-08 2003-09-24 重庆立丹(集团)药业科技开发有限公司 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN101519451B (zh) * 2005-04-05 2011-05-25 上海中信国健药业股份有限公司 重组人sCTLA4-Ig融合蛋白基因及其药物组合物
SI1868635T1 (sl) * 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
AU2008345242B2 (en) * 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
PT2222697E (pt) * 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
EP2545073B1 (en) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
KR102185854B1 (ko) 2017-09-09 2020-12-02 애플 인크. 생체측정 인증의 구현

Also Published As

Publication number Publication date
US20160264643A1 (en) 2016-09-15
US20210230250A1 (en) 2021-07-29
AU2016202816B2 (en) 2018-01-04
EP3053932B1 (en) 2020-07-22
US8329867B2 (en) 2012-12-11
WO2011103584A3 (en) 2012-07-12
ES2586579T3 (es) 2016-10-17
CN106432473A (zh) 2017-02-22
HUE030100T2 (en) 2017-04-28
DK3053932T3 (da) 2020-10-19
SMT202000572T1 (it) 2021-01-05
AU2011217770A1 (en) 2012-09-06
LT2536745T (lt) 2016-09-26
EP2536745B1 (en) 2016-05-11
US10155800B2 (en) 2018-12-18
AU2011217770B2 (en) 2016-02-04
US8629113B2 (en) 2014-01-14
CN106432473B (zh) 2021-04-02
KR101926663B1 (ko) 2018-12-07
EP3053932A1 (en) 2016-08-10
CN103038251A (zh) 2013-04-10
CN113372451B (zh) 2024-12-03
US20220348634A1 (en) 2022-11-03
CN103038251B (zh) 2016-08-17
US20190127437A1 (en) 2019-05-02
AU2016202816A1 (en) 2016-05-26
SI3053932T1 (sl) 2021-01-29
PL2536745T3 (pl) 2017-01-31
PT3053932T (pt) 2020-10-21
US20260125450A1 (en) 2026-05-07
RS61136B1 (sr) 2020-12-31
US20130089550A1 (en) 2013-04-11
HRP20160938T1 (hr) 2016-10-07
DK2536745T3 (en) 2016-08-22
WO2011103584A9 (en) 2012-08-16
SI2536745T1 (sl) 2016-10-28
US12486311B2 (en) 2025-12-02
LT3053932T (lt) 2020-11-10
US11254727B2 (en) 2022-02-22
ES2826894T3 (es) 2021-05-19
WO2011103584A2 (en) 2011-08-25
US20140112924A1 (en) 2014-04-24
EP2536745A2 (en) 2012-12-26
CA2790487C (en) 2020-10-06
HUE050768T2 (hu) 2021-01-28
US9371397B2 (en) 2016-06-21
SMT201600289B (it) 2016-11-10
JP2013520176A (ja) 2013-06-06
CN113372451A (zh) 2021-09-10
CY1118001T1 (el) 2017-05-17
CA2790487A1 (en) 2011-08-25
CY1124024T1 (el) 2022-03-24
HRP20201614T1 (hr) 2020-12-11
KR20120120993A (ko) 2012-11-02
JP5705242B2 (ja) 2015-04-22
US20110287032A1 (en) 2011-11-24
US11352412B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
PL2536745T3 (pl) Nowe immunoadhezyny CTLA4-IG
BR112013009935C8 (pt) compostos
PL2614063T3 (pl) Podstawione imidazopirydazyny
DK3225404T3 (da) Fluidpatron
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
PT2552242E (pt) Resumo
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DK2648516T3 (da) Substituerede pyridinon-pyridinylforbindelser
DE112011104226A5 (de) Käfigmutter
CO6801726A2 (es) Compuestos
CO6791565A2 (es) Anticuerpos anti-notch1
DK2649070T3 (da) Triazolpyridinforbindelser
EP2623153A4 (en) INTERCONNECTS
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
EP2584243A4 (en) INTERCONNECTS
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2448659T3 (da) Rotorskive
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE112011102711A5 (de) Hydrostataktor